Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

by Qingjun Liu, James W. Mier, David J. Panka
Published 2021-06-01

Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

by David J. Panka, Qingjun Liu, Andrew K. Geissler, James W. Mier
Published 2021-06-01

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

by Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, Xiaoen Wang, Michael P Collins, David Panka, Prabhakar Putheti, Sabina Signoretti, David C Alsop, Towia Libermann, Michael B Atkins, James W Mier, S Nahum Goldberg, Rupal S Bhatt
Published 2011-04-01

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

by Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Published 2014-01-01